64,49 €
Deine Einschätzung
Edwards Lifesciences Corp. Aktie
Was spricht für und gegen Edwards Lifesciences Corp. in den nächsten Jahren?
Pro
Kontra
Rendite von Edwards Lifesciences Corp. im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Edwards Lifesciences Corp. | 1,14 % | -3,87 % | -8,76 % | -21,18 % | -11,51 % | -23,67 % | 2,72 % |
Veeva Systems A | -0,33 % | -1,37 % | 12,67 % | 46,59 % | 20,77 % | 40,13 % | 20,50 % |
Thermo Fisher Scientific Inc. | 1,00 % | -6,37 % | -8,08 % | -35,79 % | -31,95 % | -28,81 % | 9,14 % |
Waters Corp. | 1,15 % | -2,78 % | -6,58 % | 9,77 % | -15,35 % | -2,92 % | 79,17 % |
Kommentare
News

Edwards Lifesciences to Present at the BofA Securities 2025 Health Care Conference
Edwards Lifesciences (NYSE: EW) today announced it will participate in the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025.
Bernard Zovighian, chief executive officer, and

Edwards Lifesciences Reports First Quarter Results
Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Mar. 31, 2025.
Recent Highlights
-
Q1 sales grew 6.2% to $1.41 billion, or 7.9% adjusted1
-
Q1 TAVR sales

Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025
Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2025 after the market closes on Wednesday April 23, 2025, and will host a conference call at